You are here

Novel commensal polysaccharide treats multiple sclerosis through Treg modulation

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41AI110170-01
Agency Tracking Number: R41AI110170
Amount: $322,928.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: NIAID
Solicitation Number: PA13-089
Solicitation Year: 2014
Award Year: 2014
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
BROOKLINE, MA 02445-5712
United States
DUNS: 78732474
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 (603) 653-9909
Business Contact
Phone: (617) 968-3006
Research Institution
Office of Sponsored Projects 11 Rope Ferry Rd. #6210
HANOVER, NH 03755-1421
United States

 () -
 Nonprofit college or university

Abstract Multiple sclerosis (MS) is a chronic demyelinating inflammatory disease that is the most common neurological disease of young adults, affecting over 350,000 patients in the US and over 2.5 million patients worldwide. MS is a disease of high unmetmedical need, currently treatable with one of several approved drugs, all of which result in either immune modulation or significant immunosuppression or immune ablation that can lead to serious adverse effects including opportunistic infections and malignancy. Symbiotix Biotherapies, Inc. is a startup biotechnology company developing a first-in-class therapeutic agent for MS and other immune- mediated diseases based on discoveries recently emerging from the human microbiome. Our scientific founders have identified a specific gut commensal organism, Bacteroides fragilis, that induces IL-10-secreting regulatory T cells (Treg) that are able to dampen the pro-inflammatory activities of Th1, Th2 and Th17 subsets of T cells. They have furthermore identified a sp

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government